Table 1.
Association between clinicopathologic factors and NS1-BP expression in esophageal squamous cell carcinoma (ESCC) patients
| Variables | Learning cohort [cases (%)] | Validation cohort [cases (%)] | ||||
|---|---|---|---|---|---|---|
| High expression | Low expression | P* | High expression | Low expression | P* | |
| Age (years) | 0.775 | 0.547 | ||||
| ≤ 55a | 22 (40.7) | 32 (59.3) | 10 (40.0) | 15 (60.0) | ||
| > 55 | 19 (43.1) | 25 (56.9) | 8 (38.0) | 13 (62.0) | ||
| Gender | 0.501 | 0.709 | ||||
| Male | 34 (41.5) | 48 (58.5) | 15 (36.8) | 23 (63.2) | ||
| Female | 7 (43.8) | 9 (56.2) | 3 (37.5) | 5 (62.5) | ||
| WHO grade | 0.719 | 0.660 | ||||
| G1 | 11 (45.8) | 13 (54.2) | 4 (36.4) | 7 (63.6) | ||
| G2 | 20 (40.0) | 30 (60.0) | 8 (40.0) | 12 (60.0) | ||
| G3/4 | 10 (41.7) | 14 (58.3) | 6 (40.0) | 9 (60.0) | ||
| Tumor size (cm) | 0.640 | 0.387 | ||||
| ≤ 6b | 22 (39.3) | 34 (60.7) | 13 (40.7) | 19 (59.3) | ||
| > 6 | 19 (45.2) | 23 (54.8) | 5 (35.8) | 9 (64.2) | ||
| T category | 0.541 | 0.174 | ||||
| T2 | 5 (41.7) | 7 (58.3) | 6 (50.0) | 6 (50.0) | ||
| T3 | 14 (40.0) | 21 (60.0) | 6 (33.3) | 12 (66.7) | ||
| T4 | 22 (43.1) | 29 (56.9) | 6 (37.5) | 10 (62.5) | ||
| N category | 0.622 | 0.328 | ||||
| N0 | 8 (47.1) | 9 (52.9) | 6 (42.9) | 8 (57.1) | ||
| N1 | 33 (40.8) | 48 (59.2) | 12 (37.5) | 20 (62.5) | ||
| M category | 0.352 | 0.302 | ||||
| M0 | 27 (45.8) | 32 (54.2) | 10 (41.7) | 14 (58.3) | ||
| M1-lym | 14 (35.9) | 25 (64.1) | 8 (31.9) | 14 (68.1) | ||
| CRT response | 0.007 | 0.003 | ||||
| CR | 14 (73.7) | 5 (26.3) | 8 (80.0) | 2 (20.0) | ||
| Not CR | 27 (34.2) | 52 (65.8) | 10 (27.8) | 26 (72.2) | ||
ESCC esophageal squamous cell carcinoma, T tumor, N node, M metastases, M1-lym distant lymph node metastasis, CR complete response
* χ2 test
aMean age
bMean tumor size